Genetic tests on your chronic lymphocytic leukaemia (CLL) cells

Your doctors do tests on your blood and bone marrow to look for changes in certain genes Open a glossary item. This information helps them to decide which treatment is best for you. It can also help them decide when you need to start treatment.

You might hear these tests called cytogenetic tests or molecular analysis. The doctors are looking for changes in genes and chromosomes Open a glossary item in the leukaemia cells.  

This is different to testing you to see if you have an inherited faulty gene that increases your risk of getting cancer in the first place. These genetic tests on your leukaemia cells should not be confused with tests that look for an inherited faulty gene.

Everyone should have a test to look for changes in the TP53 gene. You might also have a test to look for changes in the IGHV gene.

Why you might have these genetic tests

You might have these genetic tests on your leukaemia cells when you are first diagnosed with CLL. The results of these tests:

  • help doctors decide which type of drug might help you if you need to have treatment
  • provide information about how your CLL might behave. This helps your doctor talk to you about your outlook (prognosis)

You might need to have some genetic tests only once as the results won’t change. But the doctors repeat some tests if your CLL progresses. Again, this can help them to decide about the best treatment. This is because some genes might change over time. This is called mutating.

Types of tests

There are different types of tests.

FISH tests and other tests to look for structural changes in genes

One type is called a FISH test. FISH stands for fluorescent in situ hybridization. The FISH technique uses a special fluorescent dye. This makes it easier to see particular gene and chromosome changes.

Doctors use the FISH test to look for changes to chromosomes and genes. This includes whether part of a chromosome is missing (deleted). For example, in CLL, doctors look very carefully for deletions in chromosome 17. They also look for other structural changes - for example changes in chromosomes 11,12 and 13.

Your doctor might describe your type of CLL as a ‘complex karyotype’ if you have 3 or more changes in your chromosomes.

You might have a different type of test to look at chromosome changes depending on where you are having treatment. This might be a single nucleotide polymorphism microarray which is also called an SNP test.

Other molecular tests

DNA sequencing is another way to look for gene changes. In CLL, doctors use this test to look for faults (mutations) in certain genes. For example, they look for faults in the TP53 gene.

Doctors might also look at how many faults (mutations) are in the IGHV gene. This helps them decide if your CLL is “mutated” or “unmutated”.

What happens

You might not need any extra tests. The doctor can do genetic tests on blood samples. You have blood tests when you are diagnosed, and before each treatment.

Or they can test your bone marrow sample if you have had a bone marrow test. Your doctor will tell you if you need to have any extra tests.

Understanding your results

You might hear or read that your CLL:

  • has a TP53 mutation (mutated TP53) – this means there are changes in the TP53 gene
  • is del 17p or has a p53 deletion / mutation – this means part of chromosome 17 is missing (deleted)
  • has an IGHV mutation (mutated IGHV) – this means there are changes in the IGHV gene
  • does not have an IGHV mutation (unmutated IGHV) – this means there are no changes in the IGHV gene
  • has other structural changes or mutations

Your doctor might tell you that your genetic tests don’t show any abnormalities. This means the doctor hasn’t found any changes. But this might be because they are too small to find. Another reason could be there might be gene changes that researchers haven’t discovered yet. So a ‘normal’ result doesn’t necessarily mean you don’t have any abnormal genes.

Your doctor will talk with you about any other changes and what they mean. For example, they might find changes such as a deletion in chromosome 13. If they find this on its own, it can mean that your CLL might take longer to progress and you may not need treatment for some time.

Your doctor will talk to you about whether you need to have treatment. This also depends on many different factors such as the stage of your CLL and what symptoms you have.

If you have a TP53 mutation / del 17p and need treatment

You are likely to have a targeted cancer drug Open a glossary item. Or a targeted cancer drug with immunotherapy. Open a glossary item

If you have an IGHV mutation and need treatment

People with faulty (mutated) IGHV often never need treatment. If you do need treatment you might have a targeted cancer drug. Or a targeted cancer drug with immunotherapy.

People with faulty IGHV, who don't have any other gene changes, often respond well to all treatments. For some people, the treatment can control the CLL for a long period of time.

If you don’t have an IGHV mutation (unmutated IGHV) and need treatment

Your doctor will talk to you about your treatment options. Some treatments might not work as well if your CLL cells have an unmutated IGHV gene. This is when you compare it to people with a mutated IGHV gene.

  • Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up
    B Eichorst and others.
    Annals of Oncology, 2021. Volume 32, Issue 1 pages 22-33

  • ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

    B Eichorst and others.

    Annals of oncology, 2024. Volume 35, Issue 5

  • Chronic lymphocytic leukaemia

    N Jain and others

    The Lancet, 2024

    Published online, accessed August 2024

  • Guideline for the treatment of chronic lymphocytic leukaemia - A British Society for Haematology Guideline
    Renata Walewska and others
    British Journal of Haematology 2022, Volume 187, Issue 5, Pages 544 – 557

  • Pan-London Haemato-Oncology Clinical Guidelines
    Lymphoid Malignancies Part 4: Chronic Lymphocytic Leukaemia (CLL) and B-prolymphocytic leukaemia (B-PLL)
    South East London Cancer Alliance and others
    January 2020

  • Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

    H Döhner and others

    New England Journal of Medicine, 2000. Volume 343, number 26

Last reviewed: 
03 Oct 2024
Next review due: 
03 Oct 2027

Related links